Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
Enhances blood flow and angiogenesis Supporting faster recovery of damaged tissues
Researchers commonly hold a step longer if GI side effects are not tolerated rather than skip ahead
doi: 10.1038/s41572-019-0121-0 13 SiopiEChevalierGKatsimpardiLSahaSBigotMMoigneuCet al
US$ 29.52
US$ 21.54
US$ 22.66
US$ 21.32
US$ 23.50
US$ 23.79
US$ 23.29
US$ 27.99
